Swasthya Healthcare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Swasthya Healthcare Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $121.3K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Swasthya Healthcare Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $121.3K Trade | TransData Nexus

Swasthya Healthcare Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $121.3K Total Trade · DGFT Verified

Swasthya Healthcare Private Limited is an Indian pharmaceutical exporter with a total trade value of $121.3K across 2 products in 2 therapeutic categories. Based on 21 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Cytarabine ($65.4K), Vincristine ($55.9K), .

Swasthya Healthcare Private Limited — Export Portfolio & Destination Treemap

Swasthya Healthcare Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Swasthya Healthcare Private Limited? — Company Overview & Market Position

Swasthya Healthcare Private Limited, established on 25 September 2021, is a private limited company headquartered in Thane, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24234MH2021PTC368164. With an authorized and paid-up capital of ₹100,000, Swasthya Healthcare operates in the pharmaceutical manufacturing sector, focusing on finished pharmaceutical formulations.

The company's leadership includes Dr. Aarti Rajesh Deshpande, the Founder and CEO, who brings over 24 years of experience in the pharmaceutical industry. Under her guidance, Swasthya Healthcare has expanded its global footprint, exporting affordable generic medicines to 28 countries. The company has also established offices in Dubai, Singapore, and Latin America to enhance its international presence.

What Does Swasthya Healthcare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Cytarabine$65.4K 2Vincristine

Product Portfolio — Top 2 by Export Value

Swasthya Healthcare Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cytarabine	Advanced Oncology	$65.4K	8	0.6%	13
2	Vincristine	Oncology	$55.9K	13	2.8%	8

Swasthya Healthcare Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $121.3K. The top category is Advanced Oncology (53.9% of portfolio), followed by Oncology (46.1%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Swasthya Healthcare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Swasthya Healthcare Private Limited operates manufacturing facilities that produce a diverse range of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company emphasizes compliance with global quality standards, ensuring that its products meet the requirements of various regulatory agencies worldwide.

3Key Leadership

Dr. Aarti Rajesh Deshpande serves as the Founder and CEO of Swasthya Healthcare Private Limited. With over 24 years of experience in the pharmaceutical industry, she has represented India in pharmaceutical conclaves across more than 35 countries. Under her leadership, the company has partnered with over 100 Indian and international manufacturers, exporting affordable generic medicines to 28 countries worldwide.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Swasthya Healthcare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Swasthya Healthcare Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company holds 280 marketing authorizations worldwide, with an additional 200 registrations in the pipeline. Its products are sourced from EU-GMP and MHRA-approved manufacturing sites, ensuring compliance with stringent regulatory standards.

2Emerging Markets

Swasthya Healthcare has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's global presence includes offices in Dubai, Singapore, Guatemala, and Kazakhstan, facilitating access to these regions. By obtaining WHO prequalification, Swasthya Healthcare has enhanced its ability to supply essential medicines to these markets, contributing to improved healthcare access.

3Geographic Strategy

Swasthya Healthcare's geographic strategy involves diversification across multiple regions, including Africa, Latin America, Southeast Asia, and developed markets such as the US, EU, UK, Australia, and Japan. This approach mitigates concentration risk and positions the company to leverage growth opportunities in both emerging and established markets. The establishment of offices in Dubai, Singapore, Guatemala, and Kazakhstan underscores the company's commitment to global expansion.

Swasthya Healthcare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of March 2026, specific details regarding Swasthya Healthcare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company emphasizes compliance with global quality standards, ensuring that its products meet the requirements of various regulatory agencies worldwide.

2WHO & EU GMP

Swasthya Healthcare's products are sourced from manufacturing sites that hold EU-GMP and MHRA approvals, ensuring compliance with stringent regulatory standards. The company has obtained 280 marketing authorizations worldwide, with an additional 200 registrations in the pipeline, reflecting its commitment to meeting global quality standards.

3CDSCO & Indian Regulatory

Swasthya Healthcare Private Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian regulatory requirements. Additionally, Swasthya Healthcare obtains export No Objection Certificates (NOCs) to facilitate the international distribution of its products.

Swasthya Healthcare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Swasthya Healthcare Private Limited operates in a competitive pharmaceutical industry, focusing on finished pharmaceutical formulations. While specific competitors in overlapping categories are not detailed, the company's emphasis on affordability, quality, and a diverse product portfolio positions it favorably in the global market. The establishment of offices in Dubai, Singapore, Guatemala, and Kazakhstan enhances its competitive edge by facilitating access to various international markets.

2Key Differentiators

Swasthya Healthcare's key differentiators include its extensive experience in the pharmaceutical industry, with over 24 years of expertise represented in pharmaceutical conclaves across more than 35 countries. The company's partnerships with over 100 Indian and international manufacturers enable it to export affordable generic medicines to 28 countries worldwide. Additionally, Swasthya Healthcare's global presence, with offices in Dubai, Singapore, Guatemala, and Kazakhstan, underscores its commitment to expanding access to quality healthcare.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Swasthya Healthcare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Swasthya Healthcare Private Limited demonstrates a strong track record in the pharmaceutical industry, with over 24 years of experience and partnerships with more than 100 Indian and international manufacturers. The company's export volume and consistency are evidenced by its presence in 28 countries worldwide. Reliability indicators include compliance with global quality standards, as reflected in its EU-GMP and MHRA-approved manufacturing sites.

2Certifications to Verify

Importers should verify the following certifications when considering products from Swasthya Healthcare Private Limited:

FDA Approval: Confirm that the product is listed in the FDA's Orange Book or has an approved ANDA. Verification can be done through the FDA's official website.

WHO-GMP Certification: Ensure that the manufacturing facility holds WHO-GMP certification. This can be verified by contacting the World Health Organization or the relevant national regulatory authority.

Frequently Asked Questions — Swasthya Healthcare Private Limited

How many pharmaceutical products does Swasthya Healthcare Private Limited export from India?

Swasthya Healthcare Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Cytarabine ($65.4K), Vincristine ($55.9K). Total export value is $121.3K.

What is Swasthya Healthcare Private Limited's total pharmaceutical export value?

Swasthya Healthcare Private Limited's total pharmaceutical export value is $121.3K, based on 21 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Swasthya Healthcare Private Limited cover?

Swasthya Healthcare Private Limited exports across 2 therapeutic categories. The largest are Advanced Oncology (53.9%, 1 products), Oncology (46.1%, 1 products).

Get Full Swasthya Healthcare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.